The two most common neurodegenerative dementias are Alzheimer’s disease (AD) and dementia with Lewy bodies (DLB). There is often an overlap of symptoms across these two diseases, which can make diagnoses difficult. Although biomarkers in cerebrospinal fluid sampling and neuroimaging are the most well-validated diagnostic biomarkers, they can be invasive, time-consuming, and expensive. Researchers in Japan have discovered that the characteristics of patients’ drawing processes can discriminate between patients with AD and DLB, offering a cheap, non-invasive, and quick screening tool.